Human Genome Epidemiology Literature Finder
Records 1 - 15 (of 15 Records) |
Query Trace: Neutropenia and UGT1A[original query] |
---|
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 May 24 (15): 2237-44. Han Ji-Youn, Lim Hyeong-Seok, Shin Eun Soon, Yoo Yeon-Kyeong, Park Yong Hoon, Lee Jong-Eun, Jang In-Jin, Lee Dae Ho, Lee Jin S |
Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. Clinical colorectal cancer 2007 Jul 6 (8): 583-7. Fakih Marwan G, Ross Mary Ellen, Starostik Pe |
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenetics and genomics 2007 Jul 17 (7): 497-504. Minami Hironobu, Sai Kimie, Saeki Mayumi, Saito Yoshiro, Ozawa Shogo, Suzuki Kazuhiro, Kaniwa Nahoko, Sawada Jun-ichi, Hamaguchi Tetsuya, Yamamoto Noboru, Shirao Kuniaki, Yamada Yasuhide, Ohmatsu Hironobu, Kubota Kaoru, Yoshida Teruhiko, Ohtsu Atsushi, Saijo Nagahi |
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2007 Dec 29 (12): 913-6. Wang Yan, Xu Jian-Ming, Shen Lin, Xu Nong, Wang Jin-Wan, Jiao Shun-Chang, Zhang Jing-Sheng, Song San-Tai, Li Jian, Bao Han-Ying, Yang Lin, Li Fa |
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Apr 22 (4): 890-6. Park S R, Kong S-Y, Rhee J, Park Y-I, Ryu K W, Lee J H, Kim Y-W, Choi I J, Kim C G, Lee J Y, Cho S-J, Kim N |
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. British journal of cancer 2010 Aug 103 (4): 581-9. Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano J L, Moreno |
The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens. Cancer chemotherapy and pharmacology 2012 Jun 69 (6): 1591-9. Lamas M J, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y, Mosquera A, Giraldez J M, Lopez R, Carracedo A, Barros |
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. The Journal of pharmacology and experimental therapeutics 2013 Apr 345 (1): 95-101. Lévesque Eric, Bélanger Anne-Sophie, Harvey Mario, Couture Félix, Jonker Derek, Innocenti Federico, Cecchin Erica, Toffoli Giuseppe, Guillemette Chant |
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. The Tohoku journal of experimental medicine 2013 229 (2): 107-14. Inoue Kazuyuki, Sonobe Momoyo, Kawamura Yukinori, Etoh Takashi, Takagi Masakazu, Matsumura Takashi, Kikuyama Masataka, Kimura Midori, Minami Sato, Utsuki Hiroaki, Yamazaki Tomoaki, Suzuki Takayo, Tsuji Daiki, Hayashi Hideki, Itoh Kunihi |
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC cancer 2017 Jun 17 (1): 437. Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L |
UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. Cancer chemotherapy and pharmacology 2017 Jun 79 (6): 1109-1117. Chen Xuewei, Liu Liping, Guo Zhihua, Liang Wenhua, He Jiaxi, Huang Liyan, Deng Qiuhua, Tang Hailing, Pan Hui, Guo Minzhang, Liu Yang, He Qihua, He Jianxi |
Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case reports in oncological medicine 2017 11 2017 2683478. Jannin Arnaud, Hennart Benjamin, Adenis Antoine, Chauffert Bruno, Penel Nicol |
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. European journal of cancer (Oxford, England : 1990) 2018 Jun 99 66-77. Tejpar Sabine, Yan Pu, Piessevaux Hubert, Dietrich Daniel, Brauchli Peter, Klingbiel Dirk, Fiocca Roberto, Delorenzi Mauro, Bosman Fred, Roth Arnaud |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer medicine 2022 10 . Kanesada Kou, Tsunedomi Ryouichi, Hazama Shoichi, Ogihara Hiroyuki, Hamamoto Yoshihiko, Shindo Yoshitaro, Matsui Hiroto, Tokumitsu Yukio, Yoshida Shin, Iida Michihisa, Suzuki Nobuaki, Takeda Shigeru, Ioka Tatsuya, Nagano Hiroa |
The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics & informatics 2022 Sep 20 (3): e29. Lee Choong-Kun, Chon Hong Jae, Kwon Woo Sun, Ban Hyo-Jeong, Kim Sang Cheol, Kim Hyunwook, Jeung Hei-Cheul, Chung Jimyung, Rha Sun You |
- Page last reviewed:Feb 1, 2024
- Content source: